English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background : Autoantibodies against β 1 -adrenergic receptors (β 1 AR) that stimulate cardiac cAMP-production play a causal role in the pathogenesis of human heart failure. Patients can be subjected to specific therapies, if the presence of potentially cardio-noxious β 1 AR-autoantibodies is reliably diagnosed. This requires assessment of IgG-interactions with the native β 1 AR because β 1 AR-autoantibodies target a conformational epitope inadequately presented by denatured receptors or linear peptides. Here, we report on a standardised diagnostic procedure for the assessment of β 1 AR-autoantibodies in heart failure patients, which is based on IgG-binding to native human β 1 AR.

clinical chemistry and laboratory medicine (cclm)

A standardised FACS assay based on native, receptor transfected cells for the clinical diagnosis and monitoring of β 1 -adrenergic receptor autoantibodies in human heart disease